StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXFree Report) in a research report released on Saturday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

Shares of Cumberland Pharmaceuticals stock opened at $1.59 on Friday. The firm’s fifty day simple moving average is $1.67 and its 200-day simple moving average is $1.82. The stock has a market capitalization of $22.56 million, a price-to-earnings ratio of -2.69 and a beta of 0.17. Cumberland Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $2.36. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.37 and a quick ratio of 1.21.

Cumberland Pharmaceuticals (NASDAQ:CPIXGet Free Report) last released its quarterly earnings data on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 0.21% and a negative net margin of 21.67%. The business had revenue of $9.35 million during the quarter.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp acquired a new stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIXFree Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned approximately 0.52% of Cumberland Pharmaceuticals as of its most recent SEC filing. Institutional investors own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

(Get Free Report)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Recommended Stories

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.